A HTS assay for voltage-gated ion channel targets

超出所提供的空间。Membrane Assays, Inc. （MAI）寻求开发和商业化用于电压门控离子通道目标的高通量筛选（HTS）检测。这种分析被称为离子通道分析（ICA）。ICA利用电场刺激电压门控离子通道。利用荧光技术检测细胞反应。ICA是一种增强型96孔微孔板。在96口井的底面都有微电极。生长在井底的细胞与微电极产生电接触。当在电极之间施加电压时，细胞膜上的局部电势被改变，触发电压门控离子通道的响应。然后可以测量药物阻断、增加或减少这种反应的作用。电压门控离子通道在人类心脏跳动、肌肉收缩和和声释放等生物过程中起着至关重要的作用。因此，这些通道也是重要的药物靶点。没有一种有效的方法可以快速测试药物对电压门控离子通道的作用。传统的膜片夹紧速度太慢，即使是目前正在测试的新型自动化膜片夹产品，也不具备所需的吞吐量。结果就是错过了好药。此外，药物对心脏特定电压门控离子通道（hERG通道）的未知副作用已导致5种药物从美国市场下架。因此，即使药物的靶分子不是电压门控离子通道，潜在的新药仍然必须针对电压门控离子通道（hERG通道）进行测试，以发现副作用。MAI建议为电压门控离子通道靶标开发一种急需的HTS检测方法。该检测方法易于使用，并且与目前大多数大型制药公司的设备兼容。一期资金将用于生产100台96孔板装置。首批100台设备的制造将验证所提议的制造工艺的技术可行性，并为正在进行的生物测试和分析开发提供模板。电气测试也将进行。网站性能 ======================================== 节结束 ===========================================

EXCEED THE SPACE PROVIDED. Membrane Assays, Inc. (MAI) seeks to develop and commercialize a high throughput screening (HTS) assay for voltage-gated ion channel targets. The assay is called the Ion Channel Assay (ICA). The ICA uses an electric field to stimulate voltage-gated ion channels. The cellular response is detected optically using fluorescence technology. The ICA is an enhanced 96-well microwell plate. On the bottom surface of each of the 96 wells are microelectrodes. Cells grown on the bottom of the well make electrical contact with the microelectrodes. When a voltage is applied between the electrodes, the local electrical potential across the cellular membrane is altered triggering a response by the voltage-gated ion channels. The action of a pharmaceutical to block, increase or decrease this response can then be measured. Voltage-gated ion channels play a critical role in such biological processes as the beating of the human heart, the contraction of muscles, and the release of harmones. Therefore, these channels are also important drug targets. No effective manner of rapidly testing the action of a pharmaceutical against a voltage-gated ion channel exists. Traditional patch clamping is too slow and even the new automated patch clamp products, currently in beta testing, do not have the throughput required. The result is missed good drugs. In addition, unknown side-effects of pharmaceuticals on a particular voltage-gated ion channel in the heart, the hERG channel, have led to the removal of 5 drugs from U.S. market. Thus, even if the target molecular of a pharmaceutical is not a voltage-gated ion channel potential new drugs must still be tested against a voltage-gated ion channel, the hERG channel, to uncover side-effects. MAI proposes to develop a critically needed HTS assay for voltage-gated ion channel targets. The assay is easy to use and compatible with equipment currently in place at most large pharmaceutical companies. Phase I funds will be used to manufacture 100, 96-well plate devices. The fabrication of these first 100 devices will verify the technical feasibility of the proposed manufacturing process and provide plates for on- going biological testing and assay development. Electrical testing will also be performed. PERFORMANCE SITE ========================================Section End===========================================